Results 1 - 10 of 2000
Results 1 - 10 of 2000. Search took: 0.024 seconds
|Sort by: date | relevance|
[en] The HZ-75T Spent Fuel Shipping Cask, has been used for transporting LWR spent fuel and some of the operational experiences are described below: (1) using four units of HZ-75T, total of 34 shipments (number of casks: 67) have been made since 1979; (2) external radiation and contamination levels are sufficiently low and average turnaround at power plant site is about 4 days; (3) in-service maintenances and inspections have been carried out in accordance with the Quality Assurance Program; and (4) the operating experiences will be taken into account in the future development of LWR spent fuel shipping cask
[en] A concept, a construction and an account of commissioning experiments up to May 1993 are given for the recently completed ultra-slow positive muon facility at the pulsed muon facility of UT-MSL/KEK. The intense and slow μ+ beam with an extremely small phase-space volume to be produced in this facility will open a new muon sciences including μSR studies on material surfaces
BackgroundTwo phase 2 trials of oxaliplatin-containing adjuvant therapy for patients with gastric cancer (GC) after D2 gastrectomy were conducted in Japan. The SOXaGC trial evaluated the tolerability and safety of adjuvant therapy with S-1 plus oxaliplatin (SOX), whereas the J-CLASSIC trial evaluated the feasibility of adjuvant therapy with capecitabine plus oxaliplatin (CAPOX). Because both were studies that did not evaluate survival results as study end points, the authors evaluated the survival outcomes for the patients in the two trials.
MethodsAll 62 and 100 patients in the full analysis set of the SOXaGC and J-CLASSIC trials, respectively, were included in the current study. Their information about survival outcome was collected. The primary end point was relapse-free survival (RFS), and the secondary end point was overall survival (OS).
ResultsFor the pathologic stage (pStage 2) patients treated with CAPOX, the 3-year RFS rate was 87.8% and the 3-year OS rate was 92.7%. For the pStage 3 patients treated with SOX and CAPOX, the 3-year RFS rates were respectively 70.9% and 67.8% (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.50–1.72), whereas the 3-year OS rates were respectively 75.7% and 79.3% (HR, 1.10; 95% CI, 0.54–2.26). Subgroup analysis showed significant interactions between the treatment (SOX vs. CAPOX) and both sex (male vs. female; P = 0.024) and histologic type (diffuse vs. other, P = 0.069).
ConclusionsThis exploratory analysis demonstrated that SOX and CAPOX are suggested to have similar efficacy for pStage 3 GC patients after D2 gastrectomy. Differences in the treatment effect according to sex and histologic type warrant further evaluation.